ClinicalTrials.gov
public full text
Public Domain
Compare the Efficacy and Tolerability of the Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitors (SSRIs) Used in Major Depression
FDA has accepted atypical antipsychotics of olanzapine and aripiprazole as the adjuvant medications for refractory major depression. But there is still no trial about atypical antipsychotics combined with antidepressant of SSRI used in fresh major depressive patients. This project aims to compare the efficacy and tolerability of sertraline with or without low-dosed aripiprazole added in fresh major depression.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices#1101981
- A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices#1047221
- The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression#867701
- Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder#969799
- The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia#858032
Record · ID 834929
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive